Platinum Chemotherapy Hypersensitivity Prevalence and Management

被引：46

作者：

Otani, Iris M. ^{[1
]}

Wong, Johnson ^{[2
]}

Banerji, Aleena ^{[2
]}

机构：

[1] UCSF Med Ctr, Div Pulm Crit Care Allergy & Sleep Med, Dept Med, 400 Parnassus Ave,Fifth Floor, San Francisco, CA 94143 USA

[2] Massachusetts Gen Hosp, Div Rheumatol Allergy & Immunol, Dept Med, 55 Fruit St, Boston, MA 02114 USA

来源：

IMMUNOLOGY AND ALLERGY CLINICS OF NORTH AMERICA | 2017年 / 37卷 / 04期

关键词：

Platinum agent; Carboplatin; Cisplatin; Oxaliplatin; Chemotherapy allergy; Chemotherapy hypersensitivity; Chemotherapy desensitization; CARBOPLATIN HYPERSENSITIVITY; SKIN-TEST; RISK-STRATIFICATION; OVARIAN-CANCER; DESENSITIZATION PROTOCOL; RAPID DESENSITIZATION; CROSS-REACTIVITY; COMPLEX SALTS; OXALIPLATIN; CISPLATIN;

D O I：

10.1016/j.iac.2017.06.003

中图分类号：

R392 [医学免疫学];

学科分类号：

100102 ;

摘要：

Hypersensitivity reactions to platinum agents are common. For carboplatin and cisplatin, the first hypersensitivity reaction typically occurs around the second and third re-exposure during the second line of therapy (eighth and ninth courses overall). For oxaliplatin, the first hypersensitivity reaction can occur throughout the treatment course. Skin testing helps risk stratify patients to appropriate desensitization protocols and assess risk for breakthrough HSRs during desensitization. A risk-stratification protocol using 3 serial skin tests and desensitization protocols enables patients with platinum agent hypersensitivity to receive first-line chemotherapy treatment safely.

引用

页码：663 / +

页数：17

共 50 条

[1] An intermediate step for the management of hypersensitivity to platinum and taxane chemotherapy
Bahl, Mala
Dean, Terry
CURRENT ONCOLOGY, 2015, 22 (03) : E220 - E221
[2] Management of hypersensitivity to platinum- and taxane-based chemotherapy: CEPO review and clinical recommendations
Boulanger, J.
Boursiquot, J. N.
Cournoyer, G.
Lemieux, J.
Masse, M. S.
Almanric, K.
Guay, M. P.
CURRENT ONCOLOGY, 2014, 21 (04) : E630 - E641
[3] Chemotherapy: management of hypersensitivity and infusion reactions
Lorenz, Judith
GEBURTSHILFE UND FRAUENHEILKUNDE, 2024, 84 (01)
[4] Monoclonal Antibodies Hypersensitivity Prevalence and Management
Santos, Rafael Bonamichi
Galvao, Violeta Regnier
IMMUNOLOGY AND ALLERGY CLINICS OF NORTH AMERICA, 2017, 37 (04) : 695 - +
[5] Hypersensitivity reactions to platinum-based compounds in the context of pressurized intraperitoneal aerosol chemotherapy (PIPAC): Description and management
Gauthier, Amelie
Mankouri, Farid
Demoly, Pascal
Sgarbura, Olivia
Chiriac, Anca Mirela
ALLERGY, 2021, 76 (06) : 1882 - 1885
[6] Evaluation and management of hypersensitivity reactions to chemotherapy agents
Tham, Elizabeth Huiwen
Cheng, Yew Kuang
Tay, Miah Hiang
Alcasabas, Ana Patricia
Shek, Lynette Pei-Chi
POSTGRADUATE MEDICAL JOURNAL, 2015, 91 (1073) : 145 - 150
[7] Multidisciplinary collaboration in the establishment of a desensitization protocol: platinum chemotherapy hypersensitivity case
Mange, A. -S.
Barsagol, T.
Carreiro, M.
Staub, A.
Giamarchi, D.
Bassoua, V.
INTERNATIONAL JOURNAL OF CLINICAL PHARMACY, 2019, 41 (01) : 316 - 316
[8] Prevalence and management of aspirin hypersensitivity in a cardiology practice
Orgeron, Gabriela M.
Havistin, Ruby
Hahn, Laura S.
Wang, John
Crichlow, Candace
Mugmon, Marc
Mahajan, Anshul
Jourdan, Anthony
Sekhsaria, Sudhir
ALLERGY AND ASTHMA PROCEEDINGS, 2020, 41 (02) : 120 - 125
[9] SUCCESSFUL INDUCTION OF TOLERANCE IN PATIENTS WITH PLATINUM-BASED CHEMOTHERAPY HYPERSENSITIVITY REACTIONS
Mawhirt, S.
Sani, S.
Fonacier, L.
Calixte, R.
Davis-Lorton, M.
Aquino, M.
ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY, 2016, 117 (05) : S16 - S16
[10] PREVALENCE AND MANAGEMENT OF ASPIRIN HYPERSENSITIVITY IN THE OUTPATIENT CARDIOLOGY PRACTICE
Orgeron, G. M.
Crichlow, C.
Miller, L. S.
Wickemeyer, J.
Sekhsaria, S.
ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY, 2015, 115 (05) : A41 - A41

← 1 2 3 4 5 →